Results 11 to 20 of about 5,612,746 (351)
Journal of the National Comprehensive Cancer Network, 2009 Bladder cancer is a heterogeneous disease, with 70% of patients presenting with superficial tumours, which tend to recur but are generally not life threatening, and 30% presenting as muscle-invasive disease associated with a high risk of death from distant metastases.
James E, Montie +20 more
+9 more sources
Urology, 1996 SummaryBladder cancer is the fourth most common cancer in England and Wales. The most common presenting symptom is macroscopic haematuria. The management options for superficial and invasive bladder cancer depend on the stage at presentation. Most superficial bladder cancers are managed by transurethral resection and cytoscopic follow-up. The prognosis
H Y, Leung, T R, Griffiths, D E, Neal
openaire +4 more sources
Nature Reviews Disease Primers, 2023 Bladder cancer is a global health issue with sex differences in incidence and prognosis. Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways depending on whether the disease is non-muscle invasive or muscle invasive. The mutational burden is higher in muscle-invasive than in non-muscle-invasive disease.
Lars Dyrskjøt +6 more
openaire +2 more sources
The Scientific World JOURNAL, 2011 To review the epidemiology, diagnosis, and management of all stages of bladder cancer with an emphasis on studies published within the last year.Smoking continues to be the most important risk factor for the development of bladder cancer, and this risk has increased over time.
Todd M, Morgan +2 more
openaire +5 more sources
Bladder Cancer: Current Challenges and Future Directions
Medicina, 2021 Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the most prevalent cancers worldwide. While the clinical approach to BCa has remained largely unchanged for many years, recent discoveries have paved the way to a new era ...
J. Dobruch, M. Oszczudlowski
semanticscholar +1 more source
Overview of bladder heating technology: matching capabilities with clinical requirements. [PDF]
, 2016 Moderate temperature hyperthermia (40-45°C for 1 h) is emerging as an effective treatment to enhance best available chemotherapy strategies for bladder cancer.
Stauffer, Paul R., van Rhoon, Gerard C.
core +6 more sources
Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice. [PDF]
, 2019 Bladder cancer is among the top ten most common cancers, with about ~380,000 new cases and ~150,000 deaths per year worldwide. Tumor relapse following chemotherapy treatment has long been a significant challenge towards completely curing cancer.
de Vere White, Ralph +8 more
core +2 more sources
Functional Genomics Profiling of Bladder Urothelial Carcinoma MicroRNAome as a Potential Biomarker. [PDF]
, 2018 Though bladder urothelial carcinoma is the most common form of bladder cancer, advances in its diagnosis and treatment have been modest in the past few decades.
Li, Wei Tse +4 more
core +2 more sources
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
The Journal of the National Comprehensive Cancer Network, 2022 The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary ...
T. Flaig +37 more
semanticscholar +1 more source
Journal of the National Comprehensive Cancer Network, 2013 Bladder cancer is the fourth most common cancer in the United States. Urothelial carcinoma that originates from the urinary bladder is the most common subtype. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide recommendations on the diagnosis and management of non-muscle-invasive and muscle-invasive urothelial carcinoma of ...
Peter E, Clark +26 more
openaire +2 more sources